Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-02-20

Clinical Trial Update: An Open-Label Pharmacokinetics and Safety Study of Talazoparib [Phase 1]

View source ↗

Summary

Phase 1 open-label pharmacokinetics and safety study of talazoparib in patients with advanced solid tumors has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Talazoparib (talazoparib)

Snippet

Sponsor: Pfizer | Conditions: Advanced Solid Tumors | Phase 1 | Status: COMPLETED | Results posted: 2020-02-20